High-dose amikacin for achieving serum target levels in critically ill elderly patients.

INTRODUCTION

To achieve target concentrations, the application of higher-than-standard doses of amikacin is proposed for the treatment of sepsis due to an increase in volume of distribution and clearance, but little data are available on aminoglycoside administration in critically ill elderly patients.

PATIENTS AND METHODS

Forty critically ill elderly patients (aged over 65 years) who required amikacin therapy due to severe documented, or suspected gram-negative infections, were randomly assigned to two treatment groups. Group A (20 patients) received 15 mg/kg amikacin and Group B (20 patients) received 25 mg/kg amikacin per day as a single daily dose. All the patients were monitored for renal damage by the daily monitoring of serum creatinine. The amikacin peak (C) and trough (C) serum concentrations were measured on Days 3 and 7 postadministration.

RESULTS

Data from 18 patients in Group A and 15 patients in Group B were finally analyzed. On Day 3, the amikacin mean C levels in the standard and high-dose treatment groups were 30.4±11 and 52.3±16.1 µg/mL (<0.001), and the C levels were 3.2±2.1 and 5.2±2.8 µg/mL, respectively (=0.035). On Day 7, the C levels in the standard and high-dose groups were 33±7.3 and 60.0±17.6 µg/mL (=0.001), and the C levels were 3.2±2.9 and 9.3±5.6 µg/mL, respectively (=0.002). In only six (40%) of the patients in the high-dose groups and none of the patients in the standard-dose group, amikacin C reached the target levels (>64 µg/mL), whereas the amikacin mean C levels in the high-dose group were above the threshold of toxicity (5 µg/mL).

CONCLUSION

Our results suggest that the optimum dose of amikacin should be determined for elderly critically ill patients. It seems that higher-than-standard doses of amikacin with more extended intervals might be more appropriate than standard once-daily dosing in the elderly critically ill patients.